Brokerages forecast that KITOV PHARMA LT/S (NASDAQ:KTOV) will report earnings of ($0.01) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that KITOV PHARMA LT/S will report full year earnings of ($0.03) per share for the current financial year. For the next year, analysts anticipate that the firm will post earnings of ($0.02) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow KITOV PHARMA LT/S.

A number of research analysts recently weighed in on the company. Zacks Investment Research upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Friday, June 15th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of KITOV PHARMA LT/S in a report on Wednesday, June 6th.

KITOV PHARMA LT/S stock traded up $0.04 during midday trading on Wednesday, reaching $1.74. The stock had a trading volume of 600 shares, compared to its average volume of 98,569. KITOV PHARMA LT/S has a twelve month low of $1.60 and a twelve month high of $3.81. The stock has a market capitalization of $26.79 million, a P/E ratio of -1.34 and a beta of 2.34.


Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.

Further Reading: What is a stock buyback?

Get a free copy of the Zacks research report on KITOV PHARMA LT/S (KTOV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with's FREE daily email newsletter.